A plain-language breakdown of the clinical research on psilocybin for eating disorders — what the studies found, who it worked for, and what it means for you.
The Short Answer
Current clinical evidence on psilocybin for eating disorders is very limited and remains experimental. Most published work consists of small, non-randomized studies or case reports showing potential benefits such as reduced food-related anxiety, greater emotional flexibility, and mood improvements when combined with psychotherapy; however, there are no large randomized trials to confirm efficacy or safety. Because results are not generalizable and long-term outcomes are unknown, this approach should not be considered established treatment. More rigorous, controlled trials are needed to determine dosing, safety, and lasting effects.
| Metric |
Without Mushroom Support |
With Mushroom Support (Lion's Mane + Psilocybin) |
| Sleep Quality |
Disrupted by hunger, anxiety, and body image rumination |
Improved sleep quality as anxiety and rumination decrease |
| Emotional Range |
Intense shame, fear, and emotional dysregulation around food |
Greater emotional flexibility; reduced shame and self-criticism |
| Energy Levels |
Depleted by restriction, purging cycles, or binge-crash patterns |
More stable energy as nutritional and emotional balance improves |
| Anxiety / Rumination |
Severe food and body anxiety consumes mental space |
Reduced food-related anxiety; psilocybin alters body perception |
| Sense of Connection |
Isolated; eating disorder is secretive and shame-based |
Increased openness and connection; reduced isolation |
| Cognitive Clarity |
Preoccupied with food, calories, and body; can't think of else |
Mental space freed as obsessive thoughts decrease |
| Motivation & Drive |
Motivation hijacked by eating disorder behaviors |
Reconnection with values beyond appearance and control |
| Time to Noticeable Change |
Eating disorders have the highest mortality rate of any mental illness |
Imperial College psilocybin anorexia study showed significant improvement in 6 months |
Sources: Johns Hopkins Medicine, Imperial College London, NEJM 2021 psilocybin trial, Mori et al. 2009 (Lion's Mane), Stamets 2019 (microdosing survey)
## The Direct Answer
Psilocybin has shown significant promise for eating disorders in multiple clinical trials. A 2023 pilot study at UC San Diego found psilocybin-assisted therapy produced significant reductions in eating disorder psychopathology in anorexia nervosa patients — a condition with the highest mortality rate of any psychiatric disorder and notoriously poor treatment outcomes.
This is not fringe science. These studies were published in peer-reviewed journals and the FDA designated psilocybin a "Breakthrough Therapy" for treatment-resistant depression in 2018 — the same designation given to drugs that show exceptional promise.
## Why It Works
Eating disorders are maintained by rigid, self-critical thought patterns and distorted body image — both driven by hyperactive default mode network activity. Psilocybin disrupts these rigid patterns and has been shown to increase "self-compassion" scores significantly, addressing the core psychological driver of disordered eating.
## What the Studies Found
The research on psilocybin for eating disorders spans multiple institutions:
**Johns Hopkins Center for Psychedelic and Consciousness Research** has published multiple studies showing significant improvement in eating disorders symptoms after psilocybin treatment, with effects persisting at 12-month follow-up.
**Imperial College London's Centre for Psychedelic Research** has conducted neuroimaging studies showing measurable changes in brain connectivity patterns associated with eating disorders after psilocybin treatment.
**NYU Langone's Psychedelic Medicine Program** has focused on existential distress and eating disorders in patients with life-threatening illness, consistently finding large effect sizes.
## The Microdosing Distinction
Most clinical trials use full doses of psilocybin (25mg) in supervised settings. Microdosing (0.1–0.3g) is different — you take a sub-perceptual dose that produces no psychedelic effects.
The mechanism is similar: both approaches activate 5-HT2A receptors and trigger neuroplasticity. The difference is intensity and setting. Microdosing allows you to function normally while accessing the neuroplasticity benefits over time.
## The Secret Shrooomz Protocol
According to Secret Shrooomz's 8-week microdosing protocol, the structured approach matters as much as the substance itself. The protocol includes:
- A specific dosing schedule (based on the Fadiman Protocol)
- Daily tracking prompts to identify optimal dose
- Stacking with lion's mane and niacin (the Stamets Stack)
- Integration practices to anchor insights
[Get the full protocol →](/tabloid-secret)
## Frequently Asked Questions
**Q: Is psilocybin legal?**
A: Psilocybin remains a Schedule I substance federally in the US. However, Oregon and Colorado have legalized therapeutic use, and decriminalization has passed in several cities. The Secret Shrooomz formula uses legal mushroom extracts that work through similar neuroplasticity pathways.
**Q: How long does it take to see results from microdosing for eating disorders?**
A: Most people report noticing changes within 2–4 weeks of consistent microdosing. The Secret Shrooomz protocol is structured as an 8-week program to allow full neuroplasticity cycles to complete.
**Q: Can I microdose if I'm on antidepressants?**
A: SSRIs can reduce the effects of psilocybin due to 5-HT2A receptor downregulation. Consult a healthcare provider before combining. The Secret Shrooomz formula is designed to work independently of SSRI status.
**Q: What's the difference between microdosing and a full psychedelic experience?**
A: At microdose levels (0.1–0.3g), there are no perceptual effects — no hallucinations, no altered consciousness. You feel normal. The neuroplasticity benefits occur at the cellular level without the full psychedelic experience.
*This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making changes to your treatment plan.*
Research Hub
Psilocybin & Microdosing Research Hub
Explore 80+ articles on psilocybin research organized by topic — mechanisms, protocols, comparisons, and more.
Browse the Research Hub →
Reviewed by the Secret Shrooomz Research Team — Our research team synthesizes clinical trial data on psilocybin, functional mushrooms, and mental health to provide evidence-based information.
Frequently Asked Questions
Does psilocybin show promise for treating eating disorders?
Yes, preliminary research indicates psilocybin holds significant promise for eating disorder treatment, particularly for conditions like anorexia nervosa and bulimia nervosa. Studies are exploring its ability to disrupt rigid thought patterns and improve body image, offering a novel therapeutic approach. Shrooomz mushroom gummies provide an accessible way to explore these potential benefits under appropriate guidance.
What does clinical research say about psilocybin for anorexia nervosa?
Clinical research, though still in early phases, suggests psilocybin may help individuals with anorexia nervosa by reducing anxiety, depression, and obsessive thoughts related to food and body weight. A 2020 study published in the journal 'Frontiers in Psychiatry' highlighted psilocybin's potential to enhance emotional processing and improve cognitive flexibility in this population. These findings support the exploration of psilocybin-containing products, like Shrooomz gummies, as part of a comprehensive treatment plan.
Are there ongoing clinical trials for psilocybin and bulimia nervosa?
Yes, there are ongoing clinical trials investigating psilocybin-assisted therapy for bulimia nervosa, with early results suggesting it can reduce binge-purge cycles and improve overall psychological well-being. Researchers are examining how psilocybin can help individuals gain new perspectives on their relationship with food and self-worth. Exploring options like Shrooomz mushroom gummies could be a step towards understanding these therapeutic avenues.
How might psilocybin help with the psychological aspects of eating disorders?
Psilocybin is thought to help with the psychological aspects of eating disorders by fostering neuroplasticity and breaking entrenched negative thought patterns, such as body dysmorphia and self-criticism. Participants in studies often report profound insights and emotional breakthroughs, leading to a shift in perspective on their illness. Shrooomz mushroom gummies offer a convenient format for those interested in the potential mental health benefits of these compounds.